FDA Approves Nivolumab for Advanced Head and Neck Squamous Cell Carcinoma
The U.S. Food and Drug Administration (FDA) approved nivolumab to treat recurrent or metastatic squamous cell carcinoma of the head and neck after treatment with platinum-based therapy. The trial included 361 patients at multiple cancer centers. Compared to patients treated with traditional chemotherapy, patients who received nivolumab saw an improvement in overall survival. Read more form the ASCO Post here.
To learn more about clinical trials and the clinical trials process, visit My PearlPoint.